WO2002059268A3 - Factor ixa: factor viiia interaction and methods therefor - Google Patents

Factor ixa: factor viiia interaction and methods therefor Download PDF

Info

Publication number
WO2002059268A3
WO2002059268A3 PCT/US2002/001724 US0201724W WO02059268A3 WO 2002059268 A3 WO2002059268 A3 WO 2002059268A3 US 0201724 W US0201724 W US 0201724W WO 02059268 A3 WO02059268 A3 WO 02059268A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor
region
interaction
disclosed
ixa
Prior art date
Application number
PCT/US2002/001724
Other languages
French (fr)
Other versions
WO2002059268A2 (en
WO2002059268A9 (en
Inventor
Paul S Bajaj
Philip J Fay
Original Assignee
Univ Saint Louis
Paul S Bajaj
Philip J Fay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saint Louis, Paul S Bajaj, Philip J Fay filed Critical Univ Saint Louis
Priority to AU2002240000A priority Critical patent/AU2002240000A1/en
Priority to US10/466,998 priority patent/US20040126856A1/en
Publication of WO2002059268A2 publication Critical patent/WO2002059268A2/en
Publication of WO2002059268A3 publication Critical patent/WO2002059268A3/en
Publication of WO2002059268A9 publication Critical patent/WO2002059268A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Novel agents that inhibit the interaction of factor VIIIa with factor IXa in newly discovered regions of interaction, Region 2 and Region 3, are disclosed. The novel polypeptides or derivatives of polypeptides prevent activation of factor X and have anti-coagulation activity. The agents include polypeptides or polypeptide derivatives that are homologous to factor VIIIa or factor IXa in Region 2 and/or Region 3, as well as agents that are not homologous, such as antibodies that bind to factor VIIIa or factor IXa in Region 2 or Region 3. Pharmaceutical compositions comprising the agents are also disclosed. Methods of treatment are also disclosed, comprising the step of determining whether the compound displaces the interaction of the above agent from factor VIII or factor IX. Methods for preventing coagulation in a blood sample are also disclosed. These methods comprise adding the above agent to the sample.
PCT/US2002/001724 2001-01-23 2002-01-23 Factor ixa: factor viiia interaction and methods therefor WO2002059268A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002240000A AU2002240000A1 (en) 2001-01-23 2002-01-23 Factor ixa: factor viiia interaction and methods therefor
US10/466,998 US20040126856A1 (en) 2002-01-23 2002-01-23 Factor ixa: factor Vllla interaction and methods therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26343101P 2001-01-23 2001-01-23
US60/263,431 2001-01-23

Publications (3)

Publication Number Publication Date
WO2002059268A2 WO2002059268A2 (en) 2002-08-01
WO2002059268A3 true WO2002059268A3 (en) 2004-03-18
WO2002059268A9 WO2002059268A9 (en) 2004-04-22

Family

ID=23001740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001724 WO2002059268A2 (en) 2001-01-23 2002-01-23 Factor ixa: factor viiia interaction and methods therefor

Country Status (2)

Country Link
AU (1) AU2002240000A1 (en)
WO (1) WO2002059268A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ITO ET AL.: "Characterization of functionally important regions of tissue factor by using monoclonal antibodies", J. BIOCHEM., vol. 114, no. 5, 1993, pages 691 - 696, XP002963663 *
LOLLAR ET AL.: "Inhibition of human factor VIIIa by anti-A2 subunit antibodies", J. CLIN. INVEST., vol. 93, June 1994 (1994-06-01), pages 2497 - 2504, XP002963662 *
OUELLETTE ET AL.: "Neutralization of factor X activity by factor X specific monoclonal antibodies", BLOOD COAGULATION AND FIBRINOLYSIS, vol. 3, 1992, pages 563 - 574, XP000519286 *

Also Published As

Publication number Publication date
AU2002240000A1 (en) 2002-08-06
WO2002059268A2 (en) 2002-08-01
WO2002059268A9 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
US5866122A (en) Pharmaceutical preparation for treating blood coagulation disorders
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
WO2001045746A3 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
TR200101539T2 (en) Methods to lower serum glucose and triglyceride levels.
WO2004058769A3 (en) Triazolopyridazines as protein kinases inhibitors
ATE539744T1 (en) INHIBITORS OF SERINE PROTEASE, IN PARTICULAR HEPATITIS C VIRUS NS3-NS4A PROTEASE, WITH A CONDENSED RING SYSTEM
CO4910133A1 (en) 5-H ANTAGONISTS [1F]
DE69836199D1 (en) ANTI-INVASIVE AND ANTI-ANGIOGENIC UROKINASE FRAGMENTS AND THEIR USE
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
EP2767291A3 (en) Treatment of glycogen storage disease type II
WO2003093313A3 (en) Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
WO2000071515A3 (en) INHIBITORS OF FACTOR Xa
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
DK1194528T3 (en) Monoclonal antibody to factor VII, which, even when present in molar excess, only partially inactivates factor VII, and the method of producing such antibody
EP2083018A3 (en) Compositions and methods relating to STOP-1
WO1998012329A3 (en) Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
ATE386525T1 (en) 3-SUBSTITUTED 6,7-DIHYDROXYTETRAHYDROISOCINOLINE DERIVATIVES FOR USE AS ANTIBATERAL AGENTS
WO2002100337A3 (en) Antithrombotic thrombin variants
Erdjument et al. Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys
DE60024997D1 (en) VGF POLYPEPTIDES AND METHOD FOR THE TREATMENT OF VGF DISEASES
WO2000071716A3 (en) Vascular endothelial growth factor dimers
WO2002059268A3 (en) Factor ixa: factor viiia interaction and methods therefor
NO20002408L (en) 5-HT1F antagonists
CA2221567A1 (en) Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation
EP0239644A1 (en) Novel physiologically active substance having blood coagulation controlling activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10466998

Country of ref document: US

122 Ep: pct application non-entry in european phase
COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP